Рецепт. 2020; : 508-511
Использование новых оральных антикоагулянтов у пациентов на гемодиализе
https://doi.org/10.34883/PI.2020.23.4.005Аннотация
Показаниями к назначению антикоагулянтной терапии являются профилактика инфаркта мозга, системной тромбоэмболии при фибрилляции предсердий и тромбозе глубоких вен, которые встречаются у пациентов с терминальной стадией хронической болезни почек (ХБП) чаще, чем в общей популяции. Пациенты на гемодиализе не были включены ни в одно исследование по предупреждению инфаркта мозга и лечению венозных тромбозов, следовательно, возможное преимущество использования новых оральных антикоагулянтов (НОАК) у этой группы пациентов не выявлено. В статье описан опыт применения дабигатрана и ривароксабана у диализных пациентов.
Список литературы
1. Singh A. (2015) Approach to Patients with Chronic Kidney Disease, Stages 1–4. Handbook on dialysis. Fifth Edition. Wolters Kluwer Health, p. 8.
2. Derebail V.K., Rheault M.N., Kerlin B.A. (2020) Role of Direct Oral Anticoagulants in Patients with Kidney Disease, Kidney Int. doi: https://doi. org/10.1016/j.kint.2019.11.027.
3. Steffel J., Verhamme P., Potpara T.S. (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J., 39 (16), pp. 1330–1393. doi: 10.1093/eurheartj/ehy136
4. Krüger T., Brandenburg V., Schlieper G., Marx N., Floege J. (2013) Sailing between Scylla and Charybdis: oral long‐term anticoagulation in dialysis patients. Nephrol Dial Transplant., 28, pp. 534–41.
5. Majerus P., Tollefson D.M. (2006) Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill, pp. 1467–88.
6. Chan K.E., Giugliano R.P., Patel M.R., Nonvitamin K. (2016) Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. J Am Coll Cardiol., 67 (24), pp. 2888–2899. doi: 10.1016/j.jacc.2016.02.082
7. Ng K.P., Edwards N.C., Lip G.Y.H., Townend J.N., Ferro C.J. (2013) Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation.Am J Kidney Dis., 62, pp. 615–32.
8. Boehringer Ingelheim International GmbH (2017) Summary of product characteristics – dabigatran. Latest version.
9. Bayer Pharma AG (2016) Summary of product characteristics – rivaroxaban. Latest version.
10. Chai Adisaksopha C., Hillis C., Lim W., Boonyawat K., Moffat K., Crowther M. (2015) Hemodialysis for the treatment of dabigatran‐associated bleeding: a case report and systematic review. J Thromb Haemost., 13, pp. 1790–8.
11. Stangier J., Rathgen K., Stähle H. (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet, 49, pp. 259–68.
12. Wilson J.A.S., Goralski K.B., Soroka S.D., Morrison M., Mossop P., Sleno L. (2014) An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. J Clin Pharmacol., 54, pp. 901–9.
13. Liesenfeld K.H., Clemens A., Kreuzer J., Brueckmann M., Friedrich F. (2016) Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. Thromb Haemost., 115, pp. 562–9.
14. Perzborn E., Roehrig S., Straub A., Kubitza D., Mueck W., Laux V. (2010) Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol,30, pp. 376–81.
15. De Vriese A.S., Caluwe R., Bailleul E. (2015) Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis, 66, pp. 91–8.
16. Dias C., Moore K.T., Murphy J., Ariyawansa J., Smith W., Mills R.M. (2016) Pharmacokinetics, pharmacodynamics, and safety of single‐dose rivaroxaban in chronic hemodialysis. Am J Nephrol., 43, pp. 229–36.
17. Moore K.T., Langas M. (2018) Use of Rivaroxaban and Apixaban, Two Non-Vitamin K Antagonist Oral Anticoagulants (NOACs), in Renally Impaired Patients – the limits of our knowledge. J Cardiol Cardiovasc Med., 3, pp. 049–051. doi: 10.29328/journal.jccm.1001026
18. Coleman C.I., Kreutz R., Sood N.A. (2019) Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. Am J Med., 132 (9), pp. 1078–1083. doi: 10.1016/j.amjmed.2019.04.013
19. Ha J.T., Neuen B.L., Cheng L.P. (2019) Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med., 171 (3), pp. 181–189. doi: 10.7326/M19-0087
20. Chang S.H., Wu C.V., Yeh Y.H. (2019) Efficacy and Safety of Oral Anticoagulants in Patients With Atrial Fibrillation and Stages 4 or 5 Chronic Kidney Disease. Am J Med., 132 (11), pp. 1335–1343.e6. doi: 10.1016/j.amjmed.2019.06.006
Recipe. 2020; : 508-511
Oral Anticoagulants Use in Patients on Hemodialysis
https://doi.org/10.34883/PI.2020.23.4.005Abstract
References
1. Singh A. (2015) Approach to Patients with Chronic Kidney Disease, Stages 1–4. Handbook on dialysis. Fifth Edition. Wolters Kluwer Health, p. 8.
2. Derebail V.K., Rheault M.N., Kerlin B.A. (2020) Role of Direct Oral Anticoagulants in Patients with Kidney Disease, Kidney Int. doi: https://doi. org/10.1016/j.kint.2019.11.027.
3. Steffel J., Verhamme P., Potpara T.S. (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J., 39 (16), pp. 1330–1393. doi: 10.1093/eurheartj/ehy136
4. Krüger T., Brandenburg V., Schlieper G., Marx N., Floege J. (2013) Sailing between Scylla and Charybdis: oral long‐term anticoagulation in dialysis patients. Nephrol Dial Transplant., 28, pp. 534–41.
5. Majerus P., Tollefson D.M. (2006) Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill, pp. 1467–88.
6. Chan K.E., Giugliano R.P., Patel M.R., Nonvitamin K. (2016) Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. J Am Coll Cardiol., 67 (24), pp. 2888–2899. doi: 10.1016/j.jacc.2016.02.082
7. Ng K.P., Edwards N.C., Lip G.Y.H., Townend J.N., Ferro C.J. (2013) Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation.Am J Kidney Dis., 62, pp. 615–32.
8. Boehringer Ingelheim International GmbH (2017) Summary of product characteristics – dabigatran. Latest version.
9. Bayer Pharma AG (2016) Summary of product characteristics – rivaroxaban. Latest version.
10. Chai Adisaksopha C., Hillis C., Lim W., Boonyawat K., Moffat K., Crowther M. (2015) Hemodialysis for the treatment of dabigatran‐associated bleeding: a case report and systematic review. J Thromb Haemost., 13, pp. 1790–8.
11. Stangier J., Rathgen K., Stähle H. (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet, 49, pp. 259–68.
12. Wilson J.A.S., Goralski K.B., Soroka S.D., Morrison M., Mossop P., Sleno L. (2014) An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. J Clin Pharmacol., 54, pp. 901–9.
13. Liesenfeld K.H., Clemens A., Kreuzer J., Brueckmann M., Friedrich F. (2016) Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. Thromb Haemost., 115, pp. 562–9.
14. Perzborn E., Roehrig S., Straub A., Kubitza D., Mueck W., Laux V. (2010) Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol,30, pp. 376–81.
15. De Vriese A.S., Caluwe R., Bailleul E. (2015) Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis, 66, pp. 91–8.
16. Dias C., Moore K.T., Murphy J., Ariyawansa J., Smith W., Mills R.M. (2016) Pharmacokinetics, pharmacodynamics, and safety of single‐dose rivaroxaban in chronic hemodialysis. Am J Nephrol., 43, pp. 229–36.
17. Moore K.T., Langas M. (2018) Use of Rivaroxaban and Apixaban, Two Non-Vitamin K Antagonist Oral Anticoagulants (NOACs), in Renally Impaired Patients – the limits of our knowledge. J Cardiol Cardiovasc Med., 3, pp. 049–051. doi: 10.29328/journal.jccm.1001026
18. Coleman C.I., Kreutz R., Sood N.A. (2019) Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. Am J Med., 132 (9), pp. 1078–1083. doi: 10.1016/j.amjmed.2019.04.013
19. Ha J.T., Neuen B.L., Cheng L.P. (2019) Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med., 171 (3), pp. 181–189. doi: 10.7326/M19-0087
20. Chang S.H., Wu C.V., Yeh Y.H. (2019) Efficacy and Safety of Oral Anticoagulants in Patients With Atrial Fibrillation and Stages 4 or 5 Chronic Kidney Disease. Am J Med., 132 (11), pp. 1335–1343.e6. doi: 10.1016/j.amjmed.2019.06.006
